Questions of management of patients with hard-to-treat remitting multiple sclerosis

82 patients diagnosed with remitting multiple sclerosis, (MS) undergoing treatment with fingolimod were followed up for minimum 12 months at the Moscow Multiple Sclerosis Centre. The purpose of the follow-up was to evaluate the effects of fingolimod. 9 of 12 patients were subject to a comprehensive...

Descripció completa

Dades bibliogràfiques

Autors principals:	E. V. Popova, M. V. Melnikov, A. N. Boiko, V. V. Murugin, M. V. Paschenkov
Format:	Artigo
Idioma:	Russo
Publicat:	Remedium Group LLC 2015-12-01
Col·lecció:	Медицинский совет
Matèries:	рассеянный склероз инвалидизация обострения финголимод интерлейкин-17 препараты, изменяющие течение рассеянного склероза multiple sclerosis fingolimod interleukin-17 multiple sclerosis disease modifying drugs disability exacerbation
Accés en línia:	https://www.med-sovet.pro/jour/article/view/274
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!